4-(4-fluorophenylamino)-6-fluoro-[1,7]naphthyridine-3-carbonitrile | 915009-19-7

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二氮杂萘
• 英文名称: 4-(4-fluorophenylamino)-6-fluoro-[1,7]naphthyridine-3-carbonitrile
• 英文别名: 6-Fluoro-4-(4-fluoroanilino)-1,7-naphthyridine-3-carbonitrile
• CAS: 915009-19-7
• 化学式: C₁₅H₈F₂N₄
• 分子量: 282.252
• InChiKey: XZUXLVMEEDLDBZ-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.5
• 重原子数：
  21
• 可旋转键数：
  2
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  61.6
• 氢给体数：
  1
• 氢受体数：
  6

反应信息

• 作为反应物：
  描述：

  N-(2-氨基乙基)吗啉 、 4-(4-fluorophenylamino)-6-fluoro-[1,7]naphthyridine-3-carbonitrile 反应 1.0h， 生成 4-(4-fluorophenylamino)-6-(2-morpholinoethylamino)-1,7-naphthyridine-3-carbonitrile
  参考文献：
  名称：

  Identification of a novel class of selective Tpl2 kinase inhibitors: 4-Alkylamino-[1,7]naphthyridine-3-carbonitriles

  摘要：

  We have previously reported the discovery and initial SAR of the [1,7]naphthyridine-3-carbonitriles and quinoline-3-carbonitriles as Tumor Progression Loci-2 (Tp12) kinase inhibitors. In this paper, we report new SAR efforts which have led to the identification of 4-alkylamino-[1,7]naphthyridine-3-carbonitriles. These compounds show good in vitro and in vivo activity against Tp12 and improved pharmacokinetic properties. In addition they are highly selective for Tp12 kinase over other kinases, for example, EGFR, MEK, MK2, and p38. Lead compound 4-cycloheptylamino-6-[(pyridin-3-ylmethyl)-amino]-[1,7]naphthyridine-3-carbonit-rile (30) was efficacious in a rat model of LPS-induced TNF-alpha production. (C) 2007 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmc.2007.06.054
• 作为产物：
  描述：

  4-氟苯胺 、 4-氯-6-氟-1,7-萘啶-3-甲腈 生成 4-(4-fluorophenylamino)-6-fluoro-[1,7]naphthyridine-3-carbonitrile
  参考文献：
  名称：

  Identification of a novel class of selective Tpl2 kinase inhibitors: 4-Alkylamino-[1,7]naphthyridine-3-carbonitriles

  摘要：

  We have previously reported the discovery and initial SAR of the [1,7]naphthyridine-3-carbonitriles and quinoline-3-carbonitriles as Tumor Progression Loci-2 (Tp12) kinase inhibitors. In this paper, we report new SAR efforts which have led to the identification of 4-alkylamino-[1,7]naphthyridine-3-carbonitriles. These compounds show good in vitro and in vivo activity against Tp12 and improved pharmacokinetic properties. In addition they are highly selective for Tp12 kinase over other kinases, for example, EGFR, MEK, MK2, and p38. Lead compound 4-cycloheptylamino-6-[(pyridin-3-ylmethyl)-amino]-[1,7]naphthyridine-3-carbonit-rile (30) was efficacious in a rat model of LPS-induced TNF-alpha production. (C) 2007 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmc.2007.06.054

文献信息

• 4,6-diamino-[1,7]naphthyridine-3-carbonitrile inhibitors of Tpl2 kinase and methods of making and using the same
  申请人：Green Jeffrey Neal

  公开号：US20060276498A1

  公开（公告）日：2006-12-07

  The present invention provides compounds of formula (I): and pharmaceutically acceptable salts thereof, wherein R 1 , R 2 , R 3 , R 4 , R 5 , R 6 , m and n are defined as described herein. The invention also provides methods of making the compounds of formula (I), and methods of treating inflammatory diseases, such as rheumatoid arthritis, in a mammal comprising administering a therapeutically effective amount of a compound of formula (I) to the mammal.

  本发明提供了式(I)化合物及其药学上可接受的盐，其中R1、R2、R3、R4、R5、R6、m和n的定义如本文所述。本发明还提供了制备式(I)化合物的方法，以及治疗哺乳动物的炎症性疾病，如类风湿性关节炎的方法，包括向哺乳动物施用式(I)化合物的治疗有效量。
• 4, 6-DIAMINO-[1,7] NAPHTHYRIDINE-3-CARBONITRILE INHIBITORS OF TPL2 KINASE AND METHODS OF MAKING AND USING THE SAME
  申请人：Wyeth

  公开号：EP1881981A1

  公开（公告）日：2008-01-30
• US7432279B2
  申请人：——

  公开号：US7432279B2

  公开（公告）日：2008-10-07
• [EN] 4, 6-DIAMINO-[1,7] NAPHTHYRIDINE-3-CARBONITRILE INHIBITORS OF TPL2 KINASE AND METHODS OF MAKING AND USING THE SAME<br/>[FR] INHIBITEURS DE 4, 6-DIAMINO-[1,7] NAPHTHYRIDINE-3-CARBONITRILE DE LA TPL2 KINASE ET PROCEDES DE FABRICATION ET D'UTILISATION DE CEUX-CI
  申请人：WYETH CORP

  公开号：WO2006124944A1

  公开（公告）日：2006-11-23

  [EN] The present invention provides compounds of formula (I): and pharmaceutically acceptable salts thereof, wherein R¹, R², R³, R⁴, R⁵, R⁶, m and n are defined as described herein. The invention also provides methods of making the compounds of formula (I), and methods of treating inflammatory diseases, such as rheumatoid arthritis, in a mammal comprising administering a therapeutically effective amount of a compound of formula (I) to the mammal.
  [FR] L'invention concerne des composés de formule (I) et des sels acceptables sur le plan pharmaceutique de ceux-ci, dans laquelle R¹, R², R³, R⁴, R⁵, R⁶, m et n sont tels que définis dans la description. L'invention concerne également des procédés de fabrication des composés de formule (I) et des procédés permettant de traiter des maladies inflammatoires, telles que la polyarthrite rhumatoïde, chez un mammifère et consistant à administrer une quantité efficace sur le plan thérapeutique d'un composé de formule (I) au mammifère.
• Identification of a novel class of selective Tpl2 kinase inhibitors: 4-Alkylamino-[1,7]naphthyridine-3-carbonitriles
  作者：Neelu Kaila、Neal Green、Huan-Qiu Li、Yonghan Hu、Kristin Janz、Lori Krim Gavrin、Jennifer Thomason、Steve Tam、Dennis Powell、John Cuozzo、J. Perry Hall、Jean-Baptiste Telliez、Sang Hsu、Cheryl Nickerson-Nutter、Qin Wang、Lih-Ling Lin

  DOI：10.1016/j.bmc.2007.06.054

  日期：2007.10

  We have previously reported the discovery and initial SAR of the [1,7]naphthyridine-3-carbonitriles and quinoline-3-carbonitriles as Tumor Progression Loci-2 (Tp12) kinase inhibitors. In this paper, we report new SAR efforts which have led to the identification of 4-alkylamino-[1,7]naphthyridine-3-carbonitriles. These compounds show good in vitro and in vivo activity against Tp12 and improved pharmacokinetic properties. In addition they are highly selective for Tp12 kinase over other kinases, for example, EGFR, MEK, MK2, and p38. Lead compound 4-cycloheptylamino-6-[(pyridin-3-ylmethyl)-amino]-[1,7]naphthyridine-3-carbonit-rile (30) was efficacious in a rat model of LPS-induced TNF-alpha production. (C) 2007 Elsevier Ltd. All rights reserved.